We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
+2.04%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$681M
AUM Growth
-$84.8M
(-11%)
Cap. Flow
-$23.2M
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
54.41%
Holding
74
New
15
Increased
15
Reduced
15
Closed
16
Avg Time Held
4.2
quarters
Top 10 Avg Time Held
3.4
quarters
Top 20 Avg Time Held
4.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BridgeBio Pharma
BBIO
|
+$38.2M |
| 2 |
Autolus Therapeutics
AUTL
|
+$15.6M |
| 3 |
Immunovant
IMVT
|
+$12.3M |
| 4 |
Disc Medicine
IRON
|
+$12.1M |
| 5 |
Keros Therapeutics
KROS
|
+$9.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
+$41.5M |
| 2 |
ChemoCentryx, Inc.
CCXI
|
+$21.7M |
| 3 |
TG Therapeutics
TGTX
|
+$20.2M |
| 4 |
Cardiff Oncology
CRDF
|
+$13.2M |
| 5 |
MYOV
Myovant Sciences Ltd.
MYOV
|
+$9.85M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.89% |
| 2 | Financials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Ocular Therapeutix
OCUL
$1.59B
| $106M | 15.62% |
6,480,000
-30,000
| -0.5% | -$578K |
2019 Q1
8 quarters
|
|
2
DELISTED
Chimerix, Inc.
CMRX
| $43.3M | 6.36% |
4,490,000
+533,500
| +13% | +$4.9M |
2020 Q2
3 quarters
|
|
3
Protara Therapeutics
TARA
$155M
| $40.3M | 5.92% |
2,558,472
| – | – |
2019 Q3
6 quarters
|
|
|
4
BridgeBio Pharma
BBIO
$12.4B
| $36M | 5.28% |
+583,767
| New | +$38.2M |
2021 Q1
0 quarters
|
|
5
Codexis
CDXS
$145M
| $32M | 4.71% |
1,400,000
| – | – |
2014 Q1
28 quarters
|
|
6
Eton Pharmaceutcials
ETON
$1.52B
| $29.6M | 4.34% |
4,040,000
| – | – |
2018 Q4
9 quarters
|
|
7
MacroGenics
MGNX
$218M
| $21.2M | 3.12% |
666,200
+295,600
| +80% | +$7.18M |
2019 Q4
5 quarters
|
|
|
TCON
8
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $20.7M | 3.04% |
125,919
| – | – |
2020 Q3
2 quarters
|
|
9
Harrow
HROW
$1.06B
| $20.7M | 3.04% |
3,065,416
| – | – |
2018 Q3
10 quarters
|
|
10
Celldex Therapeutics
CLDX
$2.22B
| $20.3M | 2.98% |
985,000
-7,000
| -0.7% | -$161K |
2020 Q2
3 quarters
|
|
11
DELISTED
Xoma
XOMA
| $17.9M | 2.62% |
437,500
-17,500
| -4% | -$677K |
2017 Q1
16 quarters
|
|
12
Stereotaxis
STXS
$106M
| $17M | 2.49% |
2,526,500
-494,936
| -16% | -$2.94M |
2019 Q3
6 quarters
|
|
13
Neurogene
NGNE
$431M
| $15.1M | 2.22% |
61,250
-8,065
| -12% | -$2.06M |
2019 Q3
6 quarters
|
|
14
Fortress Biotech
FBIO
$65M
| $13.7M | 2.01% |
258,333
-834
| -0.3% | -$47K |
2020 Q2
3 quarters
|
|
15
Cytokinetics
CYTK
$8.57B
| $13.5M | 1.98% |
580,000
-2,800
| -0.5% | -$59.8K |
2020 Q2
3 quarters
|
|
|
16
Autolus Therapeutics
AUTL
$431M
| $12.1M | 1.78% |
+2,112,918
| New | +$15.6M |
2021 Q1
0 quarters
|
|
|
17
Disc Medicine
IRON
$2.17B
| $11M | 1.61% |
+27,017
| New | +$12.1M |
2021 Q1
0 quarters
|
|
18
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $9.95M | 1.46% |
222,000
| – | – |
2018 Q1
12 quarters
|
|
19
Seres Therapeutics
MCRB
$25.4M
| $9.8M | 1.44% |
15,000
-1,766
| -11% | -$813K |
2020 Q3
2 quarters
|
|
|
20
Keros Therapeutics
KROS
$223M
| $9.69M | 1.42% |
+157,500
| New | +$9.98M |
2021 Q1
0 quarters
|
|
21
DELISTED
Checkpoint Therapeutics
CKPT
| $9.19M | 1.35% |
+292,596
| New | +$9.81M |
2021 Q1
0 quarters
|
|
22
ProQR Therapeutics
PRQR
$209M
| $8.61M | 1.27% |
+1,303,000
| New | +$6.66M |
2021 Q1
0 quarters
|
|
23
DELISTED
ESSA Pharma
EPIX
| $8.25M | 1.21% |
284,050
| – | – |
2020 Q2
3 quarters
|
|
24
DELISTED
Acutus Medical Inc
AFIB
| $8.22M | 1.21% |
614,990
-135,000
| -18% | -$3.04M |
2020 Q3
2 quarters
|
|
|
ADMS
25
DELISTED
Adamas Pharmaceuticals
ADMS
| $8.02M | 1.18% |
1,670,600
+182,800
| +12% | +$955K |
2020 Q2
3 quarters
|
|
Similar funds
CFO
PFM
HBCM
HAS
AI
TPA
ZDA
NW
Opaleye Management's Q1 2021 Portfolio in Review
As of Q1 2021, Opaleye Management held 74 positions worth $681M, down 11% from $766M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Opaleye Management withdrew a net $23.2M in Q1 2021, closing 16 positions and reducing 15 holdings. Its most notable exit was Eidos Therapeutics, Inc. Common Stock, an estimated $41.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.
Against the trend, Opaleye Management opened a new position in BridgeBio Pharma worth $36M.
- Opaleye Management's largest Q1 2021 buy was BridgeBio Pharma: 583,767 shares worth $36M.
- Opaleye Management added most to MacroGenics in Q1 2021, an estimated $7.18M increase.
- Opaleye Management's biggest Q1 2021 reduction was Cardiff Oncology, cutting an estimated $13.2M.
- Opaleye Management fully exited Eidos Therapeutics, Inc. Common Stock in Q1 2021, selling an estimated $41.5M.
- Opaleye Management's ten largest holdings make up 54% of its $681M portfolio in Q1 2021.
- Opaleye Management opened 15 new positions and closed 16 in Q1 2021.
- Opaleye Management's portfolio value fell 11% quarter-over-quarter to $681M.
Based on Opaleye Management's 13F filing for Q1 2021, filed 18 May 2021.